



**Corporate presentation**  
Innovators & Investors Forum  
3 February 2015

Michael Hunt, Chief Financial Officer

# Disclaimer

THIS PRESENTATION IS CONFIDENTIAL AND IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED, FURTHER DISTRIBUTED TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE.

Neither this presentation, nor the information contained in it constitutes or forms part of an admission document or a prospectus and does not form any part of (and should not be construed as constituting or forming any part of) an offer of, or invitation to apply for, securities nor shall this document or any part of it, or the fact of its distribution, form the basis of or be relied on in connection with any investment decision, contract or commitment whatsoever. This presentation should not be considered a recommendation by ReNeuron Group Plc (the "Company") or any of its respective directors, members, officers, employees, agents or advisers in relation to any purchase of the Company's securities, including any purchase of or subscription for any ordinary shares in the capital of the Company. Accordingly, information and opinions contained in this presentation are being supplied to you solely for your information only.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been verified by the Company or any other person. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.

In the UK this presentation is being provided only to investment professional and high net worth companies, as described in articles 19 and 49(2), respectively, of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 and persons otherwise exempt under such Order.

Securities in the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or qualified for sale under the law of any state or other jurisdiction of the United States of America and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The Company does not presently intend to register any securities under the Securities Act, and no public offering of securities in the United States will be made. In the United States, this presentation is directed only at, and may be communicated only to, persons that are institutional "accredited investors" within the meaning of Rule 501(a) (1), (2), (2) or (7) under the Securities Act. Neither the United States Securities and Exchange Commission ("SEC") nor any securities regulatory body of any state or other jurisdiction of the United States of America, nor any securities regulatory body of any other country or political subdivision thereof, has passed on the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is unlawful. The distribution of this presentation in certain other jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions.

This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements and capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing.

By participating in and/or accepting delivery of this presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer.

# ReNeuron Overview

---

- A leading player globally in the high-growth field of **stem cell therapeutics**
  - Founded 1998 – quoted on AIM (RENE.L). Market cap approx £60m
  - Addressing **high-value unmet medical needs – significant market opportunities**
  - **At the forefront in stroke disability – promising clinical data**
  - Very strong underlying stem cell technology platforms
  - **Experienced management team** supported by key opinion-leading clinical advisers
  - Strong patents
  - **Significant clinical milestones targeted** over next 24 months
-

# Well-backed and well-funded

---

Principal Institutional Investors	Holding
Woodford Investment Management	20.0%
Wales Life Science Fund	11.2%
Abingworth	5.3%
Invesco	4.9%
Majedie	4.6%

- Raised £25.4 million of equity funding in July 2013
- Received £11.8 million in grant commitments in 2013
- **Funded to achieve key value inflection points within the next two years**

# Board of Directors

## Management

**Olav Hellebo** Chief Executive Officer (Clavis, UCB, Novartis, Schering-Plough)

**Michael Hunt ACA** Chief Financial Officer (Biocompatibles, Bunzl)

**Dr. John Sinden** Chief Scientific Officer and co-Founder

## Non-Executive Board

**Bryan Morton** Chairman (EUSA Pharma, Zeneus, Dechra, Oxford Biotherapeutics, BMS, Merck)

**John Berriman** (Algeta, Heptares, Abingworth)

**Simon Cartmell** (ApaTech, Celltech, Glaxo)

**Dr. Tim Corn** (EUSA Pharma, Circassia, Glaxo)

**Mark Docherty ACA** (Excalibur)

**Prof Sir Chris Evans** (Arthurian, Excalibur)


**Dr. Paul Harper** (Physiomics, Sareum, CAT, Glaxo)

# Why is Regenerative Medicine so important?


**“WE ARE ON THE BRINK OF A NEW ERA OF MEDICINE**

*Regenerative medicine represents a new paradigm in human health, with the potential to resolve unmet medical needs by addressing the underlying causes of disease.”*

The Cost Impact of an Aging Population



# Unique stem cell technology platforms



# Therapeutic pipeline





# Targeting stroke disability

---

- Stroke is the **single largest cause of adult disability** in the developed world
- Approx 800,000 people suffer a stroke in the US each year
- Annual healthcare/social care costs of stroke survivors: **>\$70 billion in the US**
- **No pharmaceutical treatment options available beyond 4 hours**
- **Blockbuster market opportunity** (multi-\$billion)
- **Pre-clinical efficacy** of our CTX cells in stroke demonstrated in **multiple studies** published in peer-reviewed scientific journals
- **Target is to improve recovery of motor function in disabled stroke survivors**

# Clinical development programme for stroke

---

- **Phase I** clinical trial completed in 11 disabled ischaemic stroke patients
- **No cell-related or immunological adverse events**
- Evidence of **sustained reductions in neurological impairment and spasticity**
- **Phase II** clinical trial to evaluate efficacy underway in the UK – first read-out in late 2015



# Targeting Critical Limb Ischaemia (CLI)

- Loss of blood flow to lower limb, leading to gangrene, amputation and death
- **Common in diabetics**
  - 160,000 legs amputated each year in the US due to CLI
  - Lifetime cost >\$0.5 million for each amputation
  - **No current treatment options except surgery (20-50% ineligible for this)**
  - **Blockbuster market opportunity** (multi-\$billion)
  - Published pre-clinical efficacy data demonstrating that **CTX cells restore blood flow**
  - **Phase I** clinical trial underway in UK – **Phase II** clinical trial planned to commence later in 2015


- **Target is to improve blood flow, leading to reduction in**
  - **incidence of death or amputation**

# Targeting Retinitis Pigmentosa (RP)

- RP is an **inherited, degenerative eye disease**
- Causes severe vision impairment and often blindness
- ReNeuron's treatment for RP has **Orphan Drug Designation** in EU and the US (market exclusivity advantages)
- Published pre-clinical data demonstrating that our hRPC cells **improve visual acuity**
- Phase I/II clinical trial scheduled




Normal vision



RP vision


# Exosomes – a new therapeutic platform

- Exosomes are nano-sized vesicles secreted by stem cells
- Thought to play a fundamental role in cell-to-cell signalling
- Exosomes can be readily harvested from CTX cell expansion process
- Therapeutic potential in tissue repair, fibrosis and cancer



# Expected clinical milestones

CTX programmes  
nRPC programme  
(retinal)  
Exosome programme



# Investment proposition

---

- **Differentiated** stem cell technology platforms – **scalable & cost effective**
- Strong competitive position – first mover, with **very high barriers to entry**
- **Significant disease targets**: blockbuster potential in stroke disability and CLI
- Building a **high-value clinical portfolio** - 3 Phase II trials across 2 platforms in the next 12 months
- **Well backed and well funded** – strong institutional shareholder base
- Strong leadership team
- Funded to reach key clinical milestones within the next 24 months, providing **significant opportunity for value build**/subsequent commercial development deals



***Thank you!***

ReNeuron  
*pioneering stem cell therapeutics*

10 Nugent Road | Surrey Research Park | Guildford | Surrey | GU2 7AF | UK

T +44 (0) 1483 302560 | E [info@reneuron.com](mailto:info@reneuron.com) | F +44 (0) 1483 534864

[www.reneuron.com](http://www.reneuron.com)

Ticker: RENE.L